Cartesian Therapeutics
RNAC
95 hedge funds and large institutions have $154M invested in Cartesian Therapeutics in 2020 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 36 increasing their positions, 23 reducing their positions, and 10 closing their positions.
160% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 10
57% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 23
20% more funds holding
Funds holding: 79 → 95 (+16)
7% more capital invested
Capital invested by funds: $144M → $154M (+$10M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.35% less ownership
Funds ownership: 1.91% → 1.56% (-0.35%)
37% less call options, than puts
Call options by funds: $353K | Put options by funds: $564K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$4.73M |
| 2 |
Morgan Stanley
New York
|
+$3.77M |
| 3 |
BlackRock
New York
|
+$3.06M |
| 4 |
Two Sigma Investments
New York
|
+$2.7M |
| 5 |
JP Morgan Chase
New York
|
+$2.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$14.9M |
| 2 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$14.7M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$5.86M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$5.13M |
| 5 |
O
OrbiMed
New York
|
-$4.49M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
UBS Group
Zurich,
Switzerland
| – | -$867 | -10 | -77% |
|
|
EI
102
Ellevest Inc
New York
| – | +$87 | +1 | New |
|
103
Simplex Trading
Chicago,
Illinois
| – | +$17K | +196 | +123% |
|
|
LJHT
104
Laurie J. Hall Trustee
| – | +$153K | +1,759 | New |
|
RNAC Hedge Fund Activity: Q4 2020 in Review
95 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q4 2020, worth a combined $154M — up 7% from $144M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new RNAC positions and 10 closed out — a net gain of 16 holders — while 36 added to existing stakes and 23 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $4.73M. The largest seller was BVF Inc, cutting an estimated $14.9M.
- 95 institutional investors held Cartesian Therapeutics (RNAC) as of Q4 2020, up from 79 in Q3 2020.
- Funds reported $154M of Cartesian Therapeutics stock for Q4 2020, up 7% quarter-over-quarter.
- 26 funds opened new Cartesian Therapeutics positions in Q4 2020 and 10 closed out, a net change of +16 holders.
- The largest Cartesian Therapeutics buyer in Q4 2020 was Armistice Capital, an estimated $4.73M added.
- The largest Cartesian Therapeutics seller in Q4 2020 was BVF Inc, an estimated $14.9M sold.
Based on aggregated 13F filings for Q4 2020.